Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386714 | 0.85 | ADORA3 (0.43) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL217858 | 0.83 | ADORA3 (0.53) | ADORA3TP53SLC29A1TDP1SIGMAR1 | |
| SCHEMBL218679 | 0.83 | ADORA3 (0.68) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL5373524 | 0.83 | ADORA3 (0.68) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL9567835 | 0.83 | ADORA3 (0.68) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL25173722 | 0.74 | SLC29A1 (0.57) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL25173742 | 0.74 | SLC29A1 (0.57) | ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL25176650 | 0.74 | ADORA1 (0.55) | ADORA3TP53SLC29A1TDP1SLC28A2 | |
| SCHEMBL25173642 | 0.74 | ADORA3 (0.57) | ADORA3TP53SLC29A1TDP1HTR2B | |
| SCHEMBL25176536 | 0.74 | ADORA3 (0.57) | ADORA3TP53SLC29A1TDP1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20230265444-A1 | GENE-EDITING IN CANNABIS PLANT | CANOPY GROWTH CORPORATION (CA) | 2023-08-24 | — | — | US | disclosed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | ADORA3 162/4885TP53 2033/4885SLC29A1 710/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | ADORA3 153/4885TP53 2134/4885SLC29A1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.